Immunotherapy in Melanoma | Specialty

The OncLive Immunotherapy in Melanoma condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in melanoma and other skin cancers. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment.

Kidney Cancer: Vaccine-Based Approaches

July 17th 2017

Novel Combinations in Kidney Cancer

July 17th 2017

Anti-VEGF/Immunotherapy Combinations in Kidney Cancer

July 17th 2017

New Strategies in Kidney Cancer

July 17th 2017

Immunotherapy in Kidney Cancer

July 17th 2017

Practical Experience With Lenvatinib/Everolimus in RCC

July 17th 2017

mTOR/TKI Combination Therapy in Kidney Cancer

July 17th 2017

Role of mTOR Inhibition in Kidney Cancer

July 17th 2017

Frontline TKI Strategies in Kidney Cancer

July 17th 2017

Kidney Cancer: Continuing to Improve Survival

July 17th 2017

Understanding the Biology of Kidney Cancer

July 17th 2017

Dermatologic Management of Melanoma Involves Observation of Skin AEs and New Primary Melanomas

July 14th 2017

Jennifer A. Stein, MD, PhD, discusses the skin-related adverse events for patients on treatment for melanoma, as well as the importance of identifying new primary melanomas.

Encouraging Activity Seen With Glembatumumab Vedotin in Advanced Melanoma

July 14th 2017

The antibody-drug conjugate glembatumumab vedotin demonstrated an 11% overall response rate in patients with refractory advanced melanoma who had received prior treatment with a checkpoint inhibitor and duration of response.

Long-Term and Brain Mets Data Demonstrate Strong Dabrafenib/Trametinib Efficacy in Melanoma

July 9th 2017

Jeffrey S. Weber, MD, PhD, discusses both pivotal studies for dabrafenib/trametinib in patients with melanoma and any unanswered questions that remain after the extensive 5-year follow-up.

Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced Melanoma

July 7th 2017

The addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate in patients with unresected stage IIIb to IV melanoma.

Dr. Schilling on the Importance of Distinguishing Ocular Melanoma

July 6th 2017

Bastian Schilling, MD, University of Wuerzburg, discusses different types of ocular melanoma and the importance of distinguishing this subtype.

Dr. Daud on the Combinations of Immunotherapy for Melanoma

July 6th 2017

Adil Daud, MD, a clinical professor, Department of Medicine at University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses potential combinations of immunotherapy for the treatment of patients with melanoma.

Pembrolizumab Demonstrates Long-Term OS Benefit in Advanced Melanoma

July 6th 2017

Pembrolizumab (Keytruda) provides a long-term survival benefit in both ipilimumab-naïve and ipilimumab-treated patients with advanced melanoma.

Adjuvant Nivolumab Improves RFS Versus Ipilimumab in Melanoma

July 5th 2017

Adjuvant nivolumab (Opdivo) extended recurrence-free survival compared with adjuvant ipilimumab (Yervoy) in patients with advanced melanoma enrolled in the phase III CheckMate-238 trial.

Expert Discusses IDO/PD-1 and Other Emerging Combos in Melanoma

June 30th 2017

Adil Daud, MD, discusses combination regimens and biomarkers being explored to advance immunotherapy in the field of melanoma.